MEHER PANJWANI’s Post

We closely examine the future of digital therapeutics and healthcare regulation in Southeast Asia and what it means for the industry.

Digital Therapeutics: The Future of Personalized, Accessible Healthcare... Digital therapeutics (DTx) refers to software-driven treatments that deliver evidence-based interventions to prevent, manage, or treat medical conditions. These therapies are often used in conjunction with medications or as stand-alone solutions, focusing on behavioral, mental health, and chronic disease management. DTx leverages technologies like 📌 mobile apps, 📌 AI, and 📌 wearable/connected devices to personalize care and provide real-time feedback to patients. In the future, digital therapeutics is expected to revolutionize healthcare by making treatments more accessible, improving patient adherence, and lowering costs. By collecting vast amounts of health data, DTx can enable more precise, individualized care, reduce hospital readmissions, and enhance preventive medicine. This shift could democratize access to high-quality healthcare, especially for those in remote or underserved areas, ultimately improving patient outcomes on a global scale. Download Deloitte's free report on digital therapeutics here: https://lnkd.in/eiHKS63h

Digital Therapeutics Market to Grow $21.9 Billion by 2028 Download Sample PDF Report-https://lnkd.in/dzCdtDBM The global digital therapeutics market in terms of revenue was estimated to be worth $6.1 billion in 2023 and is poised to reach $21.9 billion by 2028, growing at a CAGR of 29.1% from 2023 to 2028. Companies Working in the Market Etiqa     Mindset Health      Orpyx®      Bodyport      Sweetch      Neurolief     Healthcare Human Factors      Ducere Technologies   Luminopia    Five Lives      SleepUp     WTF Health        FortTeck    Sympatient Perfood Strolll Tiatros Inc. NeuroTracker    BFB Labs   Neeuro my mhealth  Persei vivarium  Day One Strategy   Prosoma  CORO HEALTH, LLC Ampersand Health INVIZA® Health — Powering Military Telehealth Connectivity™ PFG MedComm CureApp, Inc. BAYOOMED Respiree    YCare  Smileyscope  Hattrick IT Vitadio Otida MEMOTEXT Corporation

The ability to provide therapeutic intervention at scale through virtual means has been one of the most fascinating aspects of #digitalhealth. As such, the potential offered by #digitaltherapeutics led to understandable excitement in the market but we have entered the "DTx winter" as one VC recently called it. You might be forgiven for thinking I'm a little skeptical about #DTx given, for example, I organized an event entitled "should you invest in DTx?" in early 2023 in anticipation of the DTx crash but no, I'm not. 🌍 Countries/governments do not move quickly but the DiGA and PECAN schemes have, relatively speaking, been developed at light speed. European reimbursement is a reality even if the challenges remain significant. 🌐 Whilst regulation is of course territorial, most regulators now have the expertise and understanding to support an informed regulatory process. 👀 For those involved in the commercialization of DTx, there are other opportunities (that may even lead you into the wellness space) if you look up and away from selling into "the healthcare establishment" (which appears to be a tough sell in 2024). 💊 Whilst 2023 saw much reflection by pharma, there is still evidence that pharma believes DTx will help it "go beyond the pill" whilst others are focused on enhancing core processes (selling more drugs). There was a lot of "dumb money" thrown at DTx which has unfortunately tarnished the industry but I'm still optimistic. That said, whilst DTx can be a useful label for lobbying and building communities, from a #GTM perspective I feel it's an unhelpful, umbrella term as it suggests that companies/products/services have a great deal in common when the reality is that each business/product/service has unique challenges and opportunities. Are you hopeful for DTx in these choppy waters? Is the US, Europe or MENA a good bet? I always like to talk digital health so if you're free this Friday at 3pm CET and would appreciate an online "water cooler" conversation about the future of DTx, I'd be interested in your thoughts: Hop on a zoom call. https://lnkd.in/edMWnpvp Leave a like and I'll send a reminder on Friday morning.

Digital Therapeutics (DTx) Product Assessment Frameworks DTx are transforming the healthcare sector by offering software-based treatments that extend beyond conventional therapeutic approaches, marking a significant shift towards more personalized, accessible, and evidence-driven care. The unique nature of DTx, leveraging software algorithms, user interfaces, and engagement strategies, presents distinct challenges in assessing their effectiveness, safety, and impact on health outcomes. As such, there's a critical need for standardized frameworks to thoroughly evaluate DTx products, addressing these challenges and ensuring their integration into healthcare systems enhances patient care. The development of specialized assessment methodologies tailored to the digital and innovative aspects of DTx is essential. Incorporating DTx into existing Health Technology Assessment (HTA) frameworks, and adapting to new sources of evidence, will be key in overcoming these challenges, facilitating their evaluation, and maximizing their potential to improve patient outcomes. These frameworks are based on the following references: Digital Therapeutics Alliance DTx Value Assessment & Integration Guide: https://lnkd.in/dQfbdvFJ Peterson Health Technology Institute (PHTI) Assessment Framework for Digital Health Technologies: https://lnkd.in/dYPTg39i Invitation to review: Dhaval Desai, Matt Perrine, Johannes Boshkow, Emilie Lopes-Fernandes, Varun Ramdevan, Stephen Hamm, MBA, Yoann Sapanel, Scott Kellogg, Lisa Britton, MBA, Przemek Grzywa, Marguerite Manteau-Rao, LCSW, MBA, James Faux, MBA, Wes Hassan, Emanuela Kufel, Bruce Imbert MD, PhD, MPH, Abby (Captain) Doctolero, Patrick Candela, Hakim Yadi Ph.D. OBE, Ryan Douglas, Rick Bartels, MBA, Evans D. Pope, III, Brian Harris, Ed Furlong, Darren R Hocking, Ph.D., Shijun Jo, Klaudia Grzeszczak, Kalyan Kalwa, Robert A., Renata Redondo Bonaldi, PhD, Global MBA, Jessica Ackerman MS,CCC-SLP, Haresh Keswani, William Walters, Rudolf Wagner, Devanathan Raghunathan PhD MBA #healthcare #digitalhealth #healthinnovation #digitaltherapeutics #assessment

The digital therapeutics market was valued at $4.81 billion in 2023 and set to rise to $35.12 Billion by 2034 according to Precedence Research. Digital therapeutics are ideal for economically scaling gold standard treatments economically. If you, like I have, have used the #NHS services recently or read about the funding challenges (projected spend of £178 billion 2024/2025 https://lnkd.in/e2ucH79D) it might make you wonder, how does The Labour Party (Wes Streeting) thinks we can best incorporate digital health care to make a sustainable improved service.? #digitalhealth #healthcarepolicy https://lnkd.in/enfP84SQ

Digital Health, Digital Medicine, Digital Therapeutics: Not all digital health products are the same. But what are their differences? How should each product be used? What should expectations be about product outcomes? How much evidence is needed to go to market? What type of clinical evidence or regulatory oversight is necessary? https://lnkd.in/e9fGagm8 #digitalhealth #digitalmedicine #digitaltherapeutics

The future of healthcare is digital! The digital therapeutics market is set to soar to $35.12 billion by 2034! This phenomenal growth is a testament to the innovative strides we're making in harnessing technology to enhance patient care and outcomes. From personalized health apps to AI-driven treatment plans, digital therapeutics are revolutionizing how we approach healthcare. They're not just improving lives—they're saving them. Finding the right talent is crucial in this evolving field. Talentmark // Executive Recruitment excels in connecting life sciences companies with top-tier executives to drive innovation and success. Our deep industry knowledge and extensive network ensure you find the leadership needed to navigate this rapidly evolving landscape. Whether you're a life sciences professional or an investor, our purpose is to build organizations that will help humans live healthier lives for longer. Read more about the incredible potential of digital therapeutics here: https://lnkd.in/gAJMsamg #DigitalHealth #Therapeutics #Innovation #Healthcare #AI #HealthTech #TalentmarkExecutive

𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐁𝐚𝐬𝐞𝐝 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐏𝐚𝐧𝐞𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 𝐖𝐨𝐫𝐭𝐡 $𝟑𝟎 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐁𝐲 𝟐𝟎𝟑𝟎: 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲𝐀𝐑𝐂 Biomarker-Based Diagnostic Panel Market size is estimated to reach $30 billion by 2030, growing at a CAGR of 12% during the forecast period 2024-2030. The market for Biomarker-Based Diagnostic Panels is primarily driven by several key factors contributing to its growth. 👉 𝑮𝒆𝒕 𝒎𝒐𝒓𝒆 𝒊𝒏𝒇𝒐𝒓𝒎𝒂𝒕𝒊𝒐𝒏:@  https://lnkd.in/gH33d7jj #BiomarkerDiagnosis #DiagnosticPanel #PrecisionMedicine #PersonalizedMedicine #HealthcareInnovation #DiagnosticsTech #BiomarkerTesting #DiseaseDetection #ClinicalDiagnosis #MedicalInnovation #HealthTech #PrecisionHealth #DiagnosticTesting #MedicalResearch #InnovativeHealthcare

How exciting is the digital world? What role does digital therapeutics play in improving patient outcomes? How promising is this industry? What does the future look like? My comprehensive interview with TechSci Research tries to cover each of these questions and many more! P.S. It’s a long read, but would love to know your thoughts and questions in the comments.